Time between orphan drugs approval and patient access in Europe 2023, by country
This statistic displays the average time between an orphan medicine gaining marketing authorization and patient access in European countries as of January 5, 2023. According to the data, Germany had an average time of 89 days between authorization and patient access for orphan medicines (for drugs launchend from 2018 to 2021), compared to almost 1,800 days in Malta.